NanoGuardian client receives FDA approval for its nanoencryption technology
Dated: 6/27/2008
NanoGuardian said the Food and Drug Administration (FDA) has issued approval to its client to use NanoGuardian's cutting edge NanoEncryption technology as an on-dosage, brand protection technology.
NanoGuardian's NanoEncryption technology provides pharmaceutical manufacturers with true forensic, multi-layered, authentication and tracing brand protection at the individual dosage level.
NanoEncryption technology works directly on tablets, capsules and vials and captures a virtually unlimited amount of data including manufacturing information, dosage strength, expiration date, and the targeted site of distribution including country, state and specific distributor if desired.
It is complementary to on-package brand protection options such as RFID and 2-D Barcodes, providing a multi-layered, protective approach for each individual dose from plant to patient.
According to a 2006 report from the World Health Organization, an estimated $40 billion in counterfeit pharmaceuticals and an additional $15 billion in diverted products enter the pharmaceutical supply chain each year causing harmful, and at times, devastating consequences for many patients and their families.
